ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Multi-omics characterization of Yao syndrome identifies three pathophysiological axes and disease-specific divergence from Blau syndrome.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesYao syndrome (YAOS, OMIM #617321) is a NOD2-associated systemic autoinflammatory disease whose molecular pathophysiology remains uncharacterized, with no patient-level omics data reported. We performed the first integrated multi-omics characterization of YAOS.
methodsPeripheral blood mononuclear cell (PBMC) transcriptomics (RNA-seq; DESeq2), quantitative plasma proteomics (7352 proteins; DIA-MS/DIA-NN), and untargeted metabolomics (1051 MS2-annotated metabolites) were performed on six YAOS patients carrying NOD2 variants across all four functional domains (CARD, NBD, NBD-LRR junction, LRR) and healthy controls (HC). Analyses included transcription factor (TF) activity inference, CIBERSORTx immune deconvolution, co-expression network analysis, drug target mapping, and parallel transcriptomic comparison with Blau syndrome (n = 3).
resultsDespite >100-fold C-reactive protein (CRP) variation (0.31-36.34 mg/L) and regimens ranging from no treatment to quadruple immunosuppression, 600 differentially expressed genes (DEGs) were identified (|log₂FC|> 1, false discovery rate [FDR] < 0.05). NF-κB was the dominant transcriptional program (TF activity P= 0.008). Cross-platform integration identified three convergent pathophysiological axes: NF-κB/pyroptosis-driven innate immune activation (7/7 effectors directionally concordant between transcriptome and proteome), metabolic reprogramming linked to acylcarnitine accumulation (log₂FC = +0.75 to +1.42, nominal P<0.05), and gut-immune axis disruption. This inflammatory architecture persisted across all regimens examined. Drug target mapping indicated that none of the six currently targeted gene products reached transcriptomic significance, whereas three untargeted nodes-RELA, gasdermin D (GSDMD), and tyrosine kinase 2 (TYK2)-were among the most significantly upregulated (all FDR < 0.001). Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) emerged as the top co-expression hub. Parallel comparison with Blau syndrome (BS, OMIM #186580) revealed qualitatively distinct effector programs-pyroptosis execution with M1 polarization in YAOS versus inflammasome activation without pyroptosis in BS.
conclusionsThis first patient-level multi-omics characterization of a NOD2-associated autoinflammatory disease identifies a convergent, YAOS-specific inflammatory architecture and a treatment-target mismatch, generating mechanistic and therapeutic hypotheses that require validation in adequately powered cohorts.
Indexed as
Identifiers
42786248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.